Bifemelane is an antidepressant and cerebral activator that is used in Japan for the treatment of cerebral infarction patients with depressive symptoms, and in the treatment of senile dementia as well. It also appears to be useful in the treatment of glaucoma. It acts as MAOI MAO-A (Ki = 4.20 μM) (reversible) and MAO-B (Ki = 46.0 μM) (irreversible). Also acts weakly as a norepinephrine reuptake inhibitor. It is used in Japan for the treatment of cerebral infarction patients with depressive symptoms, and in the treatment of senile dementia as well. It also appears to be useful in the treatment of glaucoma. Bifemelane significantly and dose-dependently inhibited ischemic-induced depression of acetylcholine concentrations in the cerebral cortex, hippocampus, striatum, thalamus and midbrain. Compound significantly reduces the severity of ischemic brain damage.
Bifemelane hydrocloride
$20 – $7500
